Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 172,947 shares, a growth of 19.9% from the January 15th total of 144,184 shares. Based on an average trading volume of 68,792 shares, the days-to-cover ratio is presently 2.5 days. Based on an average trading volume of 68,792 shares, the days-to-cover ratio is presently 2.5 days.
Neonc Technologies Price Performance
NASDAQ NTHI opened at $8.98 on Thursday. The firm has a 50-day moving average price of $9.09 and a 200 day moving average price of $8.87. Neonc Technologies has a 52-week low of $3.20 and a 52-week high of $25.00.
Insider Buying and Selling
In other Neonc Technologies news, President Amir F. Heshmatpour bought 6,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were purchased at an average cost of $6.51 per share, for a total transaction of $39,060.00. Following the transaction, the president directly owned 2,992,000 shares of the company’s stock, valued at approximately $19,477,920. The trade was a 0.20% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of research firms have commented on NTHI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neonc Technologies in a research report on Monday, December 29th. Zacks Research raised shares of Neonc Technologies to a “hold” rating in a research note on Wednesday, January 14th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Neonc Technologies has a consensus rating of “Reduce”.
Get Our Latest Analysis on Neonc Technologies
About Neonc Technologies
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Read More
- Five stocks we like better than Neonc Technologies
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
